Ridgeback LP wins FDA clearance to commence human testing of EIDD-2801 for potential treatment for COVID-19.

Global Banking News-April 7, 2020-Ridgeback LP wins FDA clearance to commence human testing of EIDD-2801 for potential treatment for COVID-19

(C)2020 ENPublishing - http://www.enpublishing.co.uk

Biotechnology company Ridgeback Biotherapeutics LP said on Monday that it has received US Food and Drug Administration (FDA) approval to initiate human clinical testing of investigational new drug application of EIDD-2801 in the US for COVID-19.

In addition, EIDD-2801's investigational New Drug application was developed by Drug Innovation Ventures at Emory (DRIVE) LLC, which is wholly owned by Emory University and exclusively licensed to Ridgeback Biotherapeutics LP.

EIDD-2801, which is an orally available antiviral compound, prevents the replication of SARS-CoV-2, the virus that causes COVID-19 and has shown potent activity against SARS-CoV and MERS-CoV in animal models of infection. EIDD-2801 is an orally...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT